Laxmi Organic Industries (LXCHEM) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
6 Aug, 2026Executive summary
Delivered strong Q1 FY 2027 results with broad-based growth, driven by both volume and price increases across the portfolio despite global volatility and supply chain disruptions.
Successfully navigated raw material price spikes, logistics challenges, and maintained supply chain agility, ensuring business continuity.
Successfully commissioned new ethyl acetate capacity and completed scheduled maintenance at Mahad Site I.
Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and reviewed by the Board and auditors.
Dahej project progressing well, with phase II mechanical completion expected in Q3 and revenue ramp-up in FY 2028.
Financial highlights
Q1 FY 2027 consolidated revenue reached INR 9,683 million, up 40% year-over-year and 32% sequentially.
EBITDA for the quarter was INR 1,143 million, up 272% year-over-year, with margin expanding 660 bps to 37.5%.
PAT grew 216% year-over-year to INR 677 million, with PAT margin up 390 bps to 7.0%.
Specialty business revenue at INR 2,418 million (17% YoY, 13% QoQ growth); essentials at INR 7,265 million (50% YoY, 39% QoQ growth).
Volume growth contributed ~10% to revenue increase, with the remainder from price and product mix.
Outlook and guidance
Essentials business expected to deliver mid-single digit EBITDA margins over the cycle, with recent quarters showing 11%-12%.
Specialty business ramp-up to continue, with positive momentum anticipated as new capacities come online.
Dahej phase II to be capitalized in Q2, with revenue contribution expected from FY 2028.
Full-year CapEx guidance between INR 125-150 crore, including Dahej.
Tax expense for the quarter is not comparable to previous periods due to a change in tax regime and utilization of brought forward losses.
Latest events from Laxmi Organic Industries
- FY26 revenue and profit declined, but Q4 margins improved and a dividend was declared.LXCHEM
Q4 25/26 - Q3FY26 revenue and profit declined amid subdued spreads, higher costs, and major amalgamation.LXCHEM
Q3 25/26 - Q2 FY26 saw a 9% revenue drop and margin pressure, but cash flow and new projects support recovery.LXCHEM
Q2 25/26 - Q1FY26 revenue fell 4% despite 8% volume growth; CapEx and digitization advanced as planned.LXCHEM
Q1 25/26 - Q2FY25 revenue up 18%, EBITDA up 92%, and PAT up 162% amid major capex and merger progress.LXCHEM
Q2 24/25 - Q1 FY25 delivered revenue growth, specialty strength, and progress on capex, merger, and capital changes.LXCHEM
Q1 24/25 - 11% volume and 9.4% EBITDA growth, new projects, and YFCPL amalgamation mark FY25.LXCHEM
Q4 24/25 - Q3 and 9MFY25 saw double-digit growth, margin gains, and progress on expansion and corporate actions.LXCHEM
Q3 24/25